Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Serious adverse events · participants with chronic cough
1 finding from 1 review
Serious adverse events · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Intervention not reported
Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with full‐thickness rotator cuff tears
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · adults and adolescents with scrub typhus
1 finding from 1 review
Serious adverse events · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review